Exco InTouch named ‘Microsoft Managed Partner’ within life sciences

Wednesday, June 27, 2012 02:51 PM

Exco InTouch, a provider of mobile patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, has been named a Microsoft Managed Partner.

Exco has been recognized by Microsoft’s Life Science team for the company’s expertise in managing patients in regulatory and late phase clinical trials, as well as in the emerging mHealth space for marketed drugs.

Exco InTouch was selected based on a number of criteria, including the company’s established track record of providing unique solutions using cutting-edge technologies, in addition to revenue potential and growth. Exco InTouch is a global provider of regulatory compliant, simple and non-intrusive mobile patient communication solutions for clinical, late phase and mHealth studies. This enables sponsors and CROs to find and retain the right patients through engaging interactions and improved patient experience. The Managed Partner program will provide Exco InTouch with valuable resources to accelerate the adoption of its solutions in the life sciences market.

“Exco InTouch is delighted to be included in the elite group of Microsoft Managed Partners. The early access we will receive to emerging Microsoft technologies, information, tools and support will enable us to develop the most advanced patient engagement solutions to date and our customers can look forward to experiencing these benefits as our partnership with Microsoft continues,” said Tim Davis, CEO of Exco InTouch.

“As the life sciences industry continues to adapt to increased regulatory standards and a higher volume of patients, new technology solutions have the potential to revolutionize the way we manage these processes,” said Andrea McGonigle, managing director, Microsoft Life Sciences. “Exco InTouch is an example of a partner that can help companies deliver reliable data throughout their clinical and late phase studies in an accessible and user friendly way.”

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs